Association of NQO1 rs1800566 Polymorphism with Bladder and Prostate Cancers: a Systematic Review and Meta-Analysis

Mehdi Abedinzadeh, Mansour Moghimi, Mohammad Javad Akbarian-Bafghi, Majid Morovati-Sharifabad, Hossein Ahrar, Kazem Aghili, Hossein Neamatzadeh


Objective: A number of epidemiological studies have identified that rs1800566 polymorphism at NAD(P)H quinine oxidoreductase 1 (NQO1) gene is associated with risk of bladder cancer and prostate cancer, but presented inconsistent results. In order to drive a more precise estimation, the present systematic review and meta-analysis was performed.

Methods: All eligible studies were identified by searching databases including PubMed, Google Scholar, EMBASE, and CNKI up to June 2019.

Results: A total of 22 case-control studies including 15 studies on bladder cancer (4413 cases and 4275 controls) and seven studies on prostate cancer (762 cases and 1813 controls) were selected. Overall, pooled ORs showed that the NQO1 rs1800566 polymorphism is significantly associated with increased risk of bladder cancer (T vs. C: OR= 1.300, 95% CI 1.112-1.518, p=0.001; TT vs. CC: OR= 1.415, 95% CI 1.084-1.847, p=0.011; TC vs. CC: OR= 1.389, 95% CI 1.111-1.738, p0.004; TT+TC vs. CC: OR= 1.428, 95% CI 1.145-1.782, p=0.002) and prostate cancer (TC vs. CC: OR= 1.276, 95% CI 1.047-1.555, p=0.016; TT+TC vs. CC: OR= 1.268, 95% CI 1.050-1.532, p=0.014). The stratified analysis by ethnicity revealed an increased risk of bladder cancer among Caucasians and prostate cancer among Asians.

Conclusions: This meta-analysis suggests that the NQO1 rs1800566 polymorphism was significantly associated with increased risk of bladder and prostate cancers.

Klíčová slova

Bladder Cancer; Prostate Cancer; NQO1 Gene; Polymorphism; Meta-Analysis

Full Text:

PDF (English)

Na tento článek odkazuje

  • Aktuálně neexistují žádné citace.